SAB Biotherapeutics Net Income

The latest net income for SABS is $-13M as of June 2026. That compares with $-30M in the prior-year period — up 57.8% year over year. That is below the sector sector average of $86M. Investors often review this figure alongside SAB Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SABS's net income moved from $-30M to $-13M — a 57.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics's operating scale or balance-sheet position.

Against its sector companies, SABS currently prints $-13M for net income, while the sector average sits near $86M. That is roughly 114.9% below the sector mean. Large gaps often invite a closer look at SAB Biotherapeutics's growth, margins, and balance sheet.

A net income figure of $-13M for SABS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $86M. Explore the charts below for those layers of context.

After noting SABS's net income ($-13M), review year-over-year change from $-30M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.